论文部分内容阅读
目的 :探讨COPD老年患者奈替米星的药代动力学特性及其下呼吸道浓度分布。方法 :一天一次静脉滴注奈替米星 7mg/kg ,以尿素作为肺泡液稀释内标 ,用荧光偏振免疫法测定血清、支气管分泌液和肺泡液中奈替米星浓度。结果 :奈替米星 7mg/kg一天一次静脉滴注30min ,血清峰浓度 2 6 71± 4 95mg/L ,消除半衰期 3 6 9h ;肺泡液中药物峰浓度 7 76±2 1 3mg/L ,相当于血清峰浓度的 2 9% ,两者具有显著相关性 (r =0 .986 ) ,且超过常见肺炎致病菌的MIC值 ;支气管分泌液药物浓度与血清峰浓度无相关性 (r =0 .6 87)。结论 :奈替米星一天一次静脉滴注 7mg/kg用于COPD老年患者能有效治疗肺部感染
Objective: To investigate the pharmacokinetics of netilmicin in elderly patients with COPD and the distribution of its lower respiratory tract concentration. Methods: The netilmicin 7mg / kg was intravenously dripped once a day. Urea was used as an alveolar fluid to dilute the internal standard. The concentrations of netilmicin in serum, bronchial secretions and alveolar fluid were measured by fluorescence polarization immunoassay. Results: The netilmicin 7mg / kg intravenous infusion once a day for 30min, serum peak concentration 2671 ± 4 95mg / L, elimination half-life 369h; alveolar fluid peak concentration 7 76 ± 21 3mg / L, equivalent (R = 0.986), which exceeded the MIC value of common pathogenic bacteria of pneumonia. The drug concentration of bronchial excretion had no correlation with peak serum concentration (r = 0 .6 87). CONCLUSIONS: Netilmycin, an intravenous infusion of 7 mg / kg once daily, is effective in the treatment of pulmonary infections in elderly patients with COPD